DOCSLIB.ORG

Goserelin Acetate

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Goserelin Acetate Interim Revision Announcement Goserelin 1 Official May 1, 2020 min; see Table 1 for the relative retention times. Two Goserelin Acetate minor peaks are visible prior to the elution of the principal peak, System suitability solution 2.] Suitability requirements Resolution: NLT 7.0 between the goserelin and goserelin related compound A (4-D-Ser-goserelin) peaks, System suitability solution 1 Relative standard deviation: NMT 2.0% for the goserelin peak from replicate injections, Standard solution Analysis Samples: Standard solution and Sample solution Calculate the percentage of goserelin (C59H84N18O14) in the portion of Goserelin Acetate taken: C H N O · xC H O 1269.43 (as free base) 59 84 18 14 2 4 2 Result = (rU/rS) × (CS/CU) × 100 Luteinizing hormone-releasing factor (pig), 6-[O-(1,1- Dimethylethyl)-D-serine]-10-deglycinamide-, 2- rU = peak response from the Sample solution (aminocarbonyl)hydrazide, acetate (salt); rS = peak response from the Standard solution 1-(5-Oxo-L-prolyl-L-histidyl-L-tryptophyl-L-seryl-L-tyrosyl-O- CS = concentration of the Standard solution (mg/mL) tert-butyl-D-seryl-L-leucyl-L-arginyl-L-prolyl)semicarbazide C = concentration of the Sample solution (mg/mL) (goserelin free base); U Free base: [65807-02-5]. Acceptance criteria: 94.5%–103.0% on the anhydrous, Acetate salt: [145781-92-6]. acetic acid-free basis DEFINITION OTHER COMPONENTS Goserelin Acetate is a synthetic nonapeptide analog of the hypothalmic decapeptide, gonadorelin. It is obtained by Delete the following: chemical synthesis and is available as an acetate salt. It contains NLT 94.5% and NMT 103.0% of goserelin Ÿ• LIMIT OF ACETIC ACID (C59H84N18O14), calculated on the anhydrous and acetic acid- Mobile phase: Transfer 49.04 g of sulfuric acid to a 1000- free basis. mL volumetric flask, dilute with water to volume, and mix. IDENTIFICATION Accurately transfer 20 mL of this solution to a 2000-mL • A. The retention time of the goserelin peak of the Sample volumetric flask, dilute with water to volume, mix, filter, solution corresponds to that of the Standard solution, as and degas. obtained in the Assay. Standard stock solution: Transfer 2.0 mL of glacial acetic acid to a 500-mL volumetric flask, dilute with Mobile phase ASSAY to volume, and mix. Standard solution: Transfer 5.0 mL of the Standard stock Change to read: solution to a 100-mL volumetric flask, dilute with Mobile phase to volume, and mix. •PROCEDURE Sample solution: Dissolve about 20 mg of Goserelin Mobile phase: Prepare a filtered and degassed mixture of Acetate, accurately weighed, in 2–3 mL of Mobile phase. water, acetonitrile, and trifluoroacetic acid (1600:400:1). Connect a 1-mL cartridge containing packing L44 to a 1- Standard solution: 1 mg/mL of USP Goserelin Acetate RS in mL cartridge containing packing L2, which is then attached water to a suitable vacuum apparatus. With the vacuum applied, Diluted standard solution: Transfer 1 mL of the Standard wash the cartridge combination with 2 mL of methanol solution to a 10-mL volumetric flask, and dilute with water followed by 15 mL of Mobile phase, and discard the to volume. washings. Quantitatively apply the solution containing the System suitability solution 1: ŸPrepare a solution of 0.1 sample to the cartridge combination, and wash through mg/mL USP Goserelin Related Compound A RS in water, the cartridge system with several small volumes of Mobile and mix with an equal volume of Diluted standard phase. Collect the solution and washings in a 10-mL solution.Ÿ (IRA 1-May-2020) volumetric flask, and dilute with Mobile phase to volume. System suitability solution 2: ŸPrepare USP Goserelin Chromatographic system System Suitability Mixture RS as indicated on the (See Chromatography ¢621², System Suitability). label.Ÿ (IRA 1-May-2020) [NOTE—Condition the column for about 24 h until a Sample solution: 1 mg/mL of Goserelin Acetate in water stable baseline is obtained.] Chromatographic system Mode: LC (See Chromatography ¢621², System Suitability.) Detector: UV 206 nm Mode: LC Column: 7.8-mm × 30-cm; packing L17 Detector: UV 220 nm Column temperature: 65° Column: 4.6-mm × 15-cm; 3.5-μm packing L1 Flow rate: 0.8 mL/min Column temperature: 50°–55° Injection volume: 100 μL Flow rate: 1 mL/min System suitability: Injection volume: 10 μL Sample: Standard solution System suitability [NOTE—The retention time of the acetic acid peak is Samples: Standard solution, System suitability solution 1, about 11 min.] and System suitability solution 2 Suitability requirements [NOTE—For System suitability solution 1, the retention Tailing factor: NMT 2.0 time for the goserelin peak is between 40 and 50 Relative standard deviation: NMT 3.1% © 2020 The United States Pharmacopeial Convention All Rights Reserved. C211459-M35835-BIO12015 rev. 00 20200327 2 Goserelin Interim Revision Announcement Official May 1, 2020 Analysis rI = peak response for any individual impurity in the Samples: Standard solution and Sample solution Sample solution Calculate the percentage of acetic acid in the portion of rU = peak response of the main goserelin peak in the Goserelin Acetate taken by the formula: Diluted sample solution Result = (rU/rS) × (1/W) × (1.049/5) Acceptance criteria Decarbamoylgoserelin: NMT 1.0% rU = peak response from the Sample solution Any other impurity: NMT 0.5% rS = peak response from the Standard solution Total impurities: NMT 2.5% W = sample weight of Goserelin Acetate taken to prepare the Sample solution (g) and corrected (for SPECIFIC TESTS the purposes of the calculation) to eliminate the water content, which is determined immediately Change to read: prior to the test • ŸAMINO ACID CONTENT 1.049 = weight of glacial acetic acid (g/mL) (See Nuclear Magnetic Resonance Spectroscopy ¢761².) Acceptance criteria: 4.5%–15.0% Ÿ (IRA 1-May-2020) Ÿ (IRA 1-May-2020) [NOTE—Concentrations of goserelin in the Standard solution and the Sample solution must be the same Add the following: (within 5% of each other) but can be adjusted based on the quality of the carbon-13 spectra obtained. The Ÿ• ACETIC ACID IN PEPTIDES ¢503²: 4.5%– 15.0% spectra must be acquired under the same conditions Ÿ (IRA 1-May-2020) for both the Standard solution and the Sample IMPURITIES solution. The spectra obtained are of sufficient quality to allow quantification of the integrals of the Change to read: resonances specified in this test. Integrals and spectra of the Standard solution and the Sample solution can be • ORGANIC IMPURITIES: RELATED COMPOUNDS repeated and averaged.] Mobile phase, Standard solution, Diluted standard Standard solution: Dissolve USP Goserelin Acetate RS in solution, System suitability solution 1, System suitability deuterium oxide to obtain a solution having a known solution 2, Sample solution, and Chromatographic concentration of about 10% (w/v), and adjust with system: Proceed as directed in the Assay. deuterated acetic acid-d4 to a pH of 4. Diluted sample solution: Transfer 1 mL of the Sample Sample solution: Prepare a 10% (w/v) solution of Goserelin solution into a 100-mL volumetric flask, and dilute with Acetate in deuterium oxide, and adjust with deuterated water to volume. acetic acid-d4 to a pH of 4. System suitability Analysis Samples: System suitability solution 1 and System suitability Samples: Standard solution and Sample solution solution 2 Obtain a carbon-13, proton-decoupled nuclear magnetic [NOTE—For System suitability solution 1, the retention resonance (NMR) spectrum of both the Standard solution time for the goserelin peak is between 40 and 50 and the Sample solution. The spectra from the solutions min; see Table 1 for the relative retention times. For are qualitatively similar, and all the resonances from the System suitability solution 2, two peaks, spectrum of the Standard solution are present in the corresponding to decarbamoylgoserelin and 2-D-His- spectrum of the Sample solution and have the same goserelin and eluting prior to the principal peak, are chemical shift values (±0.1 ppm for goserelin, ±0.5 ppm visible.] for acetate). Identify any other resonances in the spectrum Resolution: NLT 7.0, System suitability solution 1 of the Sample solution. Integrate the resonances at the Column efficiency: NLT 2000 theoretical plates, ŸSystem approximate parts per million corresponding to each suitability solution 1Ÿ (IRA 1-May-2020) amino acid in Table 2. Tailing factor: NMT 2.0, ŸSystem suitability solution 1Ÿ (IRA 1-May-2020) Table 2 Relative standard deviation: NMT 2.0%, System Amino Acids Resonances (ppm) suitability solution 2 Azo-glycine 162.2 Table 1 Histidine 118.4 Name Relative Retention Time Tyrosine 116.7 4-D-Ser-goserelin 0.67 Ÿ tert-Butyl serine 62.2Ÿ (IRA 1-May-2020) Decarbamoylgoserelin 0.89 Ÿ Serine 62.5Ÿ (IRA 1-May-2020) 5-D-Tyr-goserelin 0.92 Tryptophan 55.7 2-D-His-goserelin 0.94 Arginine 41.8 Goserelinare 1.0 Pyroglutamic acid 26.3 Analysis Proline 26.0 Samples: Sample solution and Diluted sample solution Leucine 23.5 Calculate the percentage of goserelin-related impurities in the portion of Goserelin Acetate taken: Calculate the ratio of each of the amino acids from the integrals of the Standard solution and the Sample solution: Result = rI/rU © 2020 The United States Pharmacopeial Convention All Rights Reserved. C211459-M35835-BIO12015 rev. 00 20200327 Interim Revision Announcement Goserelin 3 Official May 1, 2020 Result = rU/rS dosage form monograph(s) in which Goserelin Acetate is used can be met. Where the label states Goserelin Acetate rU = integral of the resonance of a designated amino must be subjected to further
Load more

Recommended publications
  • Study Protocol and Documented in the Subject Dispensing Log
    Protocol Title of trial: A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study Evaluating Three Doses of Subcutaneous Pulsatile GnRH Administered via OmniPod Pump for Ovulation Induction in Female Subjects with Primary Amenorrhea with Hypogonadotropic Hypogonadism NCT number: NCT01976728 Sponsor trial code: 000070 Date: 06 Dec 2017 Gonadorelin Acetate, FE Trial Code: 000070 Date: 06 Dec 2017 999037, FE 999903 E-Protocol Amendment-21975;1.0 No Specified Dosage Form and Strength Supersedes: None Clinical Trial Protocol - Amendment 7 Page 1 of 82 CLINICAL TRIAL PROTOCOL A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study Evaluating Three Doses of Subcutaneous Pulsatile GnRH Administered via OmniPod Pump for Ovulation Induction in Female Subjects with Primary Amenorrhea with Hypogonadotropic Hypogonadism Trial Code 000070 Consolidated Protocol Incorporating Amendments 1-7 IND Number: 22,278 Investigational Medicinal Product: LutrePulse OmniPod Indication: Primary Hypothalamic Amenorrhea Phase: III Name and Address of Sponsor: Ferring International Pharmascience Center U.S., Inc. 100 Interpace Parkway Parsippany, NJ 07054 P: 973-796-1600 F: 973-796-1660 GCP Statement: This trial will be performed in compliance with GCP. The information in this document is confidential and is proprietary to Ferring International Pharmascience Center U.S. or another company within the Ferring Group. It is understood that information in this document shall not be disclosed to any third party, in any form, without prior written consent
    [Show full text]
  • Prescribing Support Information GONADORELIN ANALOGUES To
    Pending CCG approval Prescribing Support Information GONADORELIN ANALOGUES to achieve feminisation or masculinisation following assessment and diagnosis of Gender Incongruence at the NHS commissioned Cheshire and Merseyside Gender Identity Service AMBER patient retained by specialist Your patient has been identified as being suitable to receive a gonadorelin analogue in accordance with the indications detailed below. They have been started on treatment and have been reviewed to assess the efficacy and adverse effects of the treatment by the specialist team. Prescribing has been retained by the specialist team for the first 6-12 months until stabilisation of the dose and monitoring requirements has been achieved. Triptorelin is the Pan Mersey first line choice. Gonadorelin analogue treatment will continue until gonadectomy. Gonadorelin analogue treatment has been considered as appropriate for prescribing in primary care and the information contained in this document has been provided to support you to prescribe the medicine for your patient in the community. Your patient’s dose is now stable and is detailed in the attached clinic letter. There has been a significant amount of experience in the treatment of gender incongruence over the last 40 years, using several well-established hormonal protocols, and the available evidence demonstrates that, for carefully selected patients, hormone therapy is a safe and effective means of alleviating the potentially debilitating condition of gender dysphoria.1.2 Although these medicines are not licensed for the treatment of gender incongruence, they are medicines with which GPs may be familiar. Your patient will remain under the care of a specialist team within Cheshire and Merseyside Gender Identity Collaborative (CMAGIC) whilst receiving this medicine and will be able to be fast tracked back into the gender service if there are any issues.
    [Show full text]
  • Hertfordshire Medicines Management Committee (Hmmc) Nafarelin for Endometriosis Amber Initiation – Recommended for Restricted Use
    HERTFORDSHIRE MEDICINES MANAGEMENT COMMITTEE (HMMC) NAFARELIN FOR ENDOMETRIOSIS AMBER INITIATION – RECOMMENDED FOR RESTRICTED USE Name: What it is Indication Date Decision NICE / SMC generic decision status Guidance (trade) last revised Nafarelin A potent agonistic The hormonal December Final NICE NG73 2mg/ml analogue of management of 2020 Nasal Spray gonadotrophin endometriosis, (Synarel®) releasing hormone including pain relief and (GnRH) reduction of endometriotic lesions HMMC recommendation: Amber initiation across Hertfordshire (i.e. suitable for primary care prescribing after specialist initiation) as an option in endometriosis Background Information: Gonadorelin analogues (or gonadotrophin-releasing hormone agonists [GnRHas]) include buserelin, goserelin, leuprorelin, nafarelin and triptorelin. The current HMMC decision recommends triptorelin as Decapeptyl SR® injection as the gonadorelin analogue of choice within licensed indications (which include endometriosis) link to decision. A request was made by ENHT to use nafarelin nasal spray as an alternative to triptorelin intramuscular injection during the COVID-19 pandemic. The hospital would provide initial 1 month supply, then GPs would continue for further 5 months as an alternative to the patient attending for further clinic appointments for administration of triptorelin. Previously at ENHT, triptorelin was the only gonadorelin analogue on formulary for gynaecological indications. At WHHT buserelin nasal spray 150mcg/dose is RED (hospital only) for infertility & endometriosis indications. Nafarelin nasal spray 2mg/ml is licensed for: . The hormonal management of endometriosis, including pain relief and reduction of endometriotic lesions. Use in controlled ovarian stimulation programmes prior to in-vitro fertilisation, under the supervision of an infertility specialist. Use of nafarelin in endometriosis aims to induce chronic pituitary desensitisation, which gives a menopause-like state maintained over many months.
    [Show full text]
  • Tanibirumab (CUI C3490677) Add to Cart
    5/17/2018 NCI Metathesaurus Contains Exact Match Begins With Name Code Property Relationship Source ALL Advanced Search NCIm Version: 201706 Version 2.8 (using LexEVS 6.5) Home | NCIt Hierarchy | Sources | Help Suggest changes to this concept Tanibirumab (CUI C3490677) Add to Cart Table of Contents Terms & Properties Synonym Details Relationships By Source Terms & Properties Concept Unique Identifier (CUI): C3490677 NCI Thesaurus Code: C102877 (see NCI Thesaurus info) Semantic Type: Immunologic Factor Semantic Type: Amino Acid, Peptide, or Protein Semantic Type: Pharmacologic Substance NCIt Definition: A fully human monoclonal antibody targeting the vascular endothelial growth factor receptor 2 (VEGFR2), with potential antiangiogenic activity. Upon administration, tanibirumab specifically binds to VEGFR2, thereby preventing the binding of its ligand VEGF. This may result in the inhibition of tumor angiogenesis and a decrease in tumor nutrient supply. VEGFR2 is a pro-angiogenic growth factor receptor tyrosine kinase expressed by endothelial cells, while VEGF is overexpressed in many tumors and is correlated to tumor progression. PDQ Definition: A fully human monoclonal antibody targeting the vascular endothelial growth factor receptor 2 (VEGFR2), with potential antiangiogenic activity. Upon administration, tanibirumab specifically binds to VEGFR2, thereby preventing the binding of its ligand VEGF. This may result in the inhibition of tumor angiogenesis and a decrease in tumor nutrient supply. VEGFR2 is a pro-angiogenic growth factor receptor
    [Show full text]
  • Sgnrha-Ovarh-Study-Protocol.Pdf
    STUDY PROTOCOL FOR A COMPASSIONATE AQUACULTURE INVESTIGATIONAL NEW ANIMAL DRUG (INAD) EXEMPTION FOR SALMON GONADOTROPIN-RELEASING HORMONE ® ANALOGUE (sGnRHa - OvaRH ) (INAD 012-186) Sponsor: U.S. Fish and Wildlife Service, Division of Fish Hatcheries ______________________ ___________________ Sponsor Signature Date Approved Manufacturer: Western Chemical Inc. 1269 Lattimore Road Ferndale, WA Facility for Coordination of sGnRHa (OvaRH®) INAD: Aquatic Animal Drug Approval Partnership Program 4050 Bridger Canyon Road Bozeman, Mt 59715 Proposed Starting Date September 1, 2012 Proposed Ending Date August 31, 2017 Study Director Mr. Jim Bowker _________________________ ________________ Study Director Signature Date Clinical Field Trial Location and Trial Number: __________________________________________ _________________ Type or Print Facility Name Trial Number Investigator______________________________________________________ Type or Print Name __________________________________________ _________________ Investigator Signature Date I. STUDY ID AND TITLE .................................................................................................................................. 1 II. SPONSOR..................................................................................................................................................... 1 III. INVESTIGATORS/FACILITIES .................................................................................................................... 2 IV. PROPOSED STARTING AND COMPLETION DATES: ........................................................................
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 6,235,712 B1 Stevenson Et Al
    US006235.712B1 (12) United States Patent (10) Patent No.: US 6,235,712 B1 Stevenson et al. (45) Date of Patent: May 22, 2001 (54) NON-AQUEOUS POLARAPROTIC PEPTIDE Helm, et al., “Stability of Gonadorelin and Triptorelin in FORMULATIONS Aqueous Solution”, Pharm. Res., 7/12, pp. 1253-1256 (1990). (75) Inventors: Cynthia L. Stevenson; Steven J. Johnson, et al., “Degradation of the LH-RHAnalog Nafare Prestrelski, both of Mountain View, CA lin Acetate in Aqueous Solution”, Intl. J. Pharm., 31, pp. (US) 125-129 (1986). 73) Assignee:9. ALZA Corporation,p Mountain View, Lupron (leuprolide acetate for Subcutaneous injection), Phy CA (US) sician's Desk Ref, 50th Ed., pp. 2555-2556 (1996). Lupron Depot (leuprolide acetate for depot Suspension), * ) Notice: Subject to anyy disclaimer, the term of this Physician's Desk Ref, 50th Ed., pp. 2556-2562 (1996). patent is extended or adjusted under 35 Lutrepulse (gonadorelin acetate for IV injection), Physi U.S.C. 154(b) by 0 days. cian's Desk Ref, 50th Ed., pp.980–982 (1996). Okada, et al., “New Degradation Product of (21) Appl. No.: 09/514,951 Des-Gly'-NH-LH-RH-Ethylamide (Fertirelin) in Aque (22) Filed: Feb. 28, 2000 ous Solution”, J. Pharm. Sci., 80/2, pp. 167–170 (1991). Okada, et al., “Preparation of Three-Month Depot Injectable Related U.S. Application Data MicroSpheres of Leuprorelin Acetate Using Biodegradable Polymers”, Pharm. Res., 11/8, pp. 1143–1147 (1994). (62) Division of application No. 09/293,839, filed on Apr. 19, 1999, now Pat. No. 6,124,261, which is a continuation of Oyler, et al., “Characterization of the Solution Degradation application No.
    [Show full text]
  • Triptorelin, Goserelin and Leuprorelin for Prostate
    789FM.1 GONADORELIN ANALOGUES (GnRHa): TRIPTORELIN, GOSERELIN, LEUPRORELIN FOR PROSTATE CANCER - AMBER RECOMMENDATION GUIDELINE This guideline provides prescribing and monitoring guidance for triptorelin, goserelin and Leuprorelin use in prostate cancer. It should be read in conjunction with the Summary of Product Characteristics (SPC), available on www.medicines.org.uk/emc, and the BNF. BACKGROUND AND INDICATIONS FOR USE There is no conclusive evidence to suggest that any one GnRHa is more effective or has fewer side effects than another for the treatment of prostate cancer.5, 7-9 Available evidence suggests that GnRHa are similar in effectiveness to surgical castration. They have the same licensed indications in the treatment of prostate cancer (Appendix 1). Appendix 2 compares doses, administration frequency and costs.1-4, 9-13 Triptorelin 22.5 mg (six monthly injection) is the 1st choice GnRHa for treatment of metastatic prostate cancer patients on life-long treatment on the Bucks formulary. This is because it is: • Administered via a smaller sized needle (20 gauge) compared to goserelin LA 10.8 mg (14 gauge), thus minimising discomfort to patients.9 • The least expensive in terms of drug and administration costs (Appendix 2).1-4, 9-13 Triptorelin 22.5 mg (six monthly injection) is not preferred in: • Patients newly initiated GnRHa because the first dose should be a monthly preparation (Decapeptyl® SR 3 mg) in order to check that the product is tolerated prior to changing to the six monthly preparation.14 • Anticoagulated patients. This is because triptorelin is an intramuscular (IM) injection. Subcutaneously administered GnRHa (goserelin or leuprorelin) may be preferable.9 RESPONSIBILITIES Hospital specialist 1.
    [Show full text]
  • Study of Enteral Versus Parenteral Application of The
    Journal of Reproduction and Development, Vol. 53, No. 3, 2007 —Research Note— Study of Enteral versus Parenteral Application of the Gonadotropin Releasing Hormone Agonist Gonadorelin[6-D-Phe] (D-Phe6-LHRH) on LH Secretion in Goettinger Miniature Pigs Klaus-Peter BRÜSSOW1), Ellen KANITZ2), Armin TUCHSCHERER3) and Petra TOSCH4) Departments of 1)Reproductive Biology, 2)Behavioural Physiology and 3)Genetic and Biometry, FBN Research Institute for the Biology of Farm Animals, D-18196 Dummerstorf, Germany and 4)VetCom-pharma GmbH, 6900 Bregenz, Austria Abstract. With respect to the assessment of residue situation and as a part of preclinical trials to determine the biological activities of potential gonadotropin releasing hormone (GnRH) residues in porcine organisms the GnRH agonist Gonadorelin[6-D-Phe] (D-Phe6-LHRH) was administered either enterally or intramuscularly (i.m.) to female Goettinger miniature pigs in order to evaluate the GnRH- induced luteinizing hormone (LH) surge. Gilts received an (i) enteral application of 10 mg D-Phe6- LHRH via a probang (enteral group, n=7), (ii) i.m. injection of 0.1 mg D-Phe6-LHRH (parenteral group, n= 5), or (iii) saline injection (control group, n=4). The GnRH and saline applications were repeated every second day with up to seven repetitions. Blood samples were collected via previously fitted jugular catheters immediately before injections, over an 8 h period in 1 h intervals beginning 2 h after injections, and at 24, 26, 28 and 30 h after applications. Enteral application of D-Phe6-LHRH induced an LH surge in 23 of 30 treatments. All gilts in the parenteral group exhibited LH release after each D- Phe6-LHRH application (P<0.05), whereas no LH surges were observed after saline injection in the control group.
    [Show full text]
  • Gnrh Analogues for Treatment of Urinary
    Europäisches Patentamt *EP001330257B1* (19) European Patent Office Office européen des brevets (11) EP 1 330 257 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.7: A61K 38/09, A61K 45/06, of the grant of the patent: A61P 13/00 31.08.2005 Bulletin 2005/35 (86) International application number: (21) Application number: 01975948.9 PCT/CH2001/000636 (22) Date of filing: 26.10.2001 (87) International publication number: WO 2002/036144 (10.05.2002 Gazette 2002/19) (54) GNRH ANALOGUES FOR TREATMENT OF URINARY INCONTINENCE VERWENDUNG VON GNRH-ANALOGUE ZUR BEHANDLUNG DER HARNINKONTINENZ UTILISATION D’ANALOGUES DE GNRH DANS LE TRAITEMENT DE L’INCONTINENCE URINAIRE (84) Designated Contracting States: (74) Representative: Isler & Pedrazzini AG AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU Gotthardstrasse 53 MC NL PT SE TR Postfach 6940 8002 Zürich (CH) (30) Priority: 30.10.2000 EP 00811011 (56) References cited: (43) Date of publication of application: WO-A-99/55358 30.07.2003 Bulletin 2003/31 • JANSSENS L A ET AL: "Comparisons between (73) Proprietor: UNIVERSITY OF ZURICH stress incontinence in women and sphincter 8006 Zürich (CH) mechanism incompetence in the female dog." VETERINARY RECORD, (1997 DEC 13) 141 (24) (72) Inventors: 620-5. REF: 93 , XP001061849 • ARNOLD, Susi • CONN P M ET AL: CH-5115 Möriken AG (CH) "GONADOTROPIN-RELEASINGHORMONEAND • REICHLER, Iris ITS ANALOGUES" NEW ENGLAND JOURNAL CH-8057 Zürich (CH) OF MEDICINE, THE, MASSACHUSETTS • HUBLER, Madeleine MEDICAL SOCIETY, WALTHAM, MA, US, vol. CH-8342 Wernetshausen (CH) 324, 10 January 1991 (1991-01-10), pages 93-103, XP001002186 ISSN: 0028-4793 Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted.
    [Show full text]
  • Gonadorelin Analogues for Prostate and Breast Cancer
    Nottinghamshire Area Prescribing Committee statement regarding prescribing of Gonadorelin analogues (GnRH) and degarelix in Primary Care for Prostate and Breast Cancer • Triptorelin (Decapeptyl SR®) is currently the most cost-effective gonadorelin analogue. • As long as the gonadorelin analogue is being prescribed for a licensed indication, it is acceptable for the GP to prescribe the most cost effective product, even if this is different from that originally recommended by secondary care. Therapy should be switched when the next dose of gonadorelin analogue is due. • Goserelin 3.6mg (Zoladex®) is currently the only product which is included on the formulary and licensed for breast cancer. As such, breast cancer patients should remain on goserelin 3.6mg subcutaneously every month unless directed otherwise by secondary care. • Degarelix (Firmagon®) is a GnRH antagonist and is an option for treating advanced hormone-dependent prostate cancer in people with spinal metastases. Background Triptorelin, leuprorelin and goserelin are gonadotrophin releasing hormone (GnRH) analogues that are licensed for administration either monthly, 3-monthly or 6- monthly in the treatment of a number of indications. A summary of their licensed indications and administration schedules is given in Appendix 1. Triptorelin is classified as Amber 2 (specialist initiation) for the indication of prostate cancer with the other GnRH analogues classified Grey for this indication. Goserelin is classified as Amber 2 (specialist initiation) for breast cancer. The first dose of GnRH analogue will be given in secondary care. Other indications are classified as Red and prescribing should remain within secondary care. Degarelix is a GnRH antagonist and was approved for use in line with NICE TA404 in 2016.
    [Show full text]
  • Multi-Discipline Review
    CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 212099Orig1s000 MULTI-DISCIPLINE REVIEW Summary Review Office Director Cross Discipline Team Leader Review Clinical Review Non-Clinical Review Statistical Review Clinical Pharmacology Review NDA 212099 Multi-disciplinary Review and Evaluation Darolutamide/NUBEQA NDA/BLA Multi-Disciplinary Review and Evaluation Application Type NDA Application Number(s) 212099 Priority or Standard Priority Submit Date(s) February 26, 2019 Received Date(s) February 26. 2019 PDUFA Goal Date August 26, 2019 Division/Office Division of Oncology Products 1/Office of Hematology & Oncology Products Review Completion Date Established/Proper Name Darolutamide (Proposed) Trade Name Nubeqa Pharmacologic Class Androgen receptor inhibitor Code name 427492003 | Hormone refractory prostate cancer (disorder) Applicant Bayer Doseage form 300 mg tablets Applicant proposed Dosing NUBEQA 600 mg, (two 300 mg tablets) administered orally Regimen twice daily. Swallow tablets whole. Take NUBEQA with food. Patients should also receive a gonadotropin-releasing hormone (GnRH) analog concurrently or should have had bilateral orchiectomy. Applicant Proposed NUBEQA is an androgen receptor inhibitor indicated for the Indication(s)/Population(s) treatment of patients with non-metastatic castration-resistant prostate cancer. Applicant Proposed Non-metastatic castration resistant prostate cancer (nmCRPC) SNOMED CT Indication Disease Term for each Proposed Indication Recommendation on Regular approval Regulatory Action Recommended
    [Show full text]
  • Reproductive Endocrinology of the Dog
    Reproductive endocrinology of the dog Effects of medical and surgical intervention Jeffrey de Gier 2011 Cover: Anjolieke Dertien, Multimedia; photos: Jeffrey de Gier Lay-out: Nicole Nijhuis, Gildeprint Drukkerijen, Enschede Printing: Gildeprint Drukkerijen, Enschede De Gier, J., Reproductive endocrinology of the dog, effects of medical and surgical intervention, PhD thesis, Faculty of Veterinary Medicine, Utrecht University, Utrecht, The Netherlands Copyright © 2011 J. de Gier, Utrecht, The Netherlands ISBN: 978-90-393-5687-6 Correspondence and requests for reprints: [email protected] Reproductive endocrinology of the dog Effects of medical and surgical intervention Endocrinologie van de voortplanting van de hond Effecten van medicamenteus en chirurgisch ingrijpen (met een samenvatting in het Nederlands) Proefschrift ter verkrijging van de graad van doctor aan de Universiteit Utrecht op gezag van de rector magnificus, prof.dr. G.J. van der Zwaan, ingevolge het besluit van het college voor promoties in het openbaar te verdedigen op dinsdag 20 december 2011 des middags te 12.45 uur door Jeffrey de Gier geboren op 14 mei 1973 te ’s-Gravenhage Promotor: Prof.dr. J. Rothuizen Co-promotoren: Dr. H.S. Kooistra Dr. A.C. Schaefers-Okkens Publication of this thesis was made possible by the generous financial support of: AUV Dierenartsencoöperatie Boehringer Ingelheim B.V. Dechra Veterinary Products B.V. J.E. Jurriaanse Stichting Merial B.V. MSD Animal Health Novartis Consumer Health B.V. Royal Canin Nederland B.V. Virbac Nederland B.V. Voor mijn ouders
    [Show full text]